<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807858</url>
  </required_header>
  <id_info>
    <org_study_id>68/16.Oct.2012</org_study_id>
    <nct_id>NCT01807858</nct_id>
  </id_info>
  <brief_title>The Effects of Synbiotics on Morbidity and Mortality in Preterm Infants</brief_title>
  <official_title>The Effects of Synbiotics on Morbidity and Mortality in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Sami Ulus Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Sami Ulus Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study, the inclusion of very low birth weight premature infants followed in Dr.Sami Ulus
      Maternity and Children Training and Research Hospital, Department of Neonatology; be
      randomized to very low birth weight premature infants began eating until you are discharged
      from the hospital once a day to feed a group+ 900 mg of 5 billion active Bifidobacterium
      lactis, the addition of chicory inulin, in the other group given placebo; Patients taking
      weekly blood cultures, the presence of residues in both groups during feeding, to evaluate
      the incidence of NEC and sepsis are planned. Randomization and the number of patients planned
      to separate into groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients separated into four groups using the sealed envelope method.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Necrotizing enterocolitis</measure>
    <time_frame>8 weeks</time_frame>
    <description>Developing of &gt;= grade 2 necrotizing enterocolitis suggested by radiological investigation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>16 weeks</time_frame>
    <description>length of hospital stay</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Necrotizing Enterocolitis</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Bifidobacterium lactis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 billion Bifidobacterium lactis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>İnulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>900 mg İnulin per day will be given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bifidobacterium lactis plus İnülin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 billion active Bifidobacterium lactis plus 900 mg İnülin per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium lactis</intervention_name>
    <description>5 billion active Bifidobacterium lactis</description>
    <arm_group_label>İnulin</arm_group_label>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_label>Bifidobacterium lactis plus İnülin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium lactis plus İnülin</intervention_name>
    <description>5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given</description>
    <arm_group_label>Bifidobacterium lactis</arm_group_label>
    <arm_group_label>İnulin</arm_group_label>
    <arm_group_label>Maltodextrin</arm_group_label>
    <other_name>5 billion Bifidobacterium lactis plus 900 mg İnülin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Maltodextrin</description>
    <arm_group_label>Bifidobacterium lactis</arm_group_label>
    <arm_group_label>İnulin</arm_group_label>
    <arm_group_label>Bifidobacterium lactis plus İnülin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>İnulin</intervention_name>
    <description>900 mg inulin per day will be given</description>
    <arm_group_label>Bifidobacterium lactis</arm_group_label>
    <arm_group_label>Maltodextrin</arm_group_label>
    <arm_group_label>Bifidobacterium lactis plus İnülin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  VLBW infants admitted to NICU at the first 7 days of life

        Exclusion Criteria:

          -  expected life lower than 7 days,

          -  babies who could not be fed (any metabolic disorders, gastrointestinal system surgical
             disorders etc.),

          -  severe asphyxia,

          -  severe congenital anomaly
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dilek Dilli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assoc Prof</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dilek Dilli, Assoc Prof</last_name>
    <phone>00903123055000</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Şevket Yılmaz Research Hospital</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arzu Akdağ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Arzu Akdağ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Diyarbakır Research Hospital</name>
      <address>
        <city>Diyarbakır</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Banu Mutlu, MD</last_name>
    </contact>
    <investigator>
      <last_name>M. Şah Oğuz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Okmeydani Research Hospital</name>
      <address>
        <city>İstanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Özden Turan, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Özden Turan</last_name>
    </contact_backup>
    <investigator>
      <last_name>Özden Turan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Umraniye Research Hospital</name>
      <address>
        <city>İstanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Şenol Bozdağ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Şenol Bozdağ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.livestrong.com/article/468506-are-probiotics-safe-for-newborns/</url>
    <description>Are Probiotics Safe For Newborns? | LIVESTRONG.COM</description>
  </link>
  <reference>
    <citation>Fouhy F, Ross RP, Fitzgerald GF, Stanton C, Cotter PD. Composition of the early intestinal microbiota: knowledge, knowledge gaps and the use of high-throughput sequencing to address these gaps. Gut Microbes. 2012 May-Jun;3(3):203-20. doi: 10.4161/gmic.20169. Epub 2012 May 1. Review.</citation>
    <PMID>22572829</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <last_update_submitted>March 7, 2013</last_update_submitted>
  <last_update_submitted_qc>March 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. Sami Ulus Children's Hospital</investigator_affiliation>
    <investigator_full_name>Dilek Dilli</investigator_full_name>
    <investigator_title>Assoc Prof</investigator_title>
  </responsible_party>
  <keyword>Necrotizing enterocolitis</keyword>
  <keyword>Sepsis</keyword>
  <keyword>Length of hospital stay</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>August 1, 2014</submitted>
    <returned>August 19, 2014</returned>
    <submitted>August 20, 2014</submitted>
    <returned>August 31, 2014</returned>
    <submitted>February 19, 2015</submitted>
    <returned>March 4, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

